LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Kodu・Aktsiate loetelu・Amgen Inc

Amgen Inc

Suletud

SektorTervishoid

326.2 -3.03

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

325.13

Max

336.3

Põhinäitajad
By Trading Economics
Sissetulek	486M 1.8B
Müük	-1.3B 8.6B
P/E Sektori keskmine	22.936 51.415
Aktsiakasum	5.15
Dividenditootlus	2.91
Kasumimarginaal	21.107
Töötajad	31,500
EBITDA	-2.3B 2.7B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+8.47% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.91% 2.34%
Järgmine tulemuste avaldamine	4. aug 2026
Järgmine dividendimakse kuupäev	5. juuni 2026

Turustatistika
By TradingEconomics
Turukapital	-5.4B 178B
Eelmine avamishind	329.23
Eelmine sulgemishind	326.2

Uudiste sentiment

By Acuity

32%

68%

81 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

270.44 / 276.44 Toetus ja vastupanu

Amgen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 20:16 UTC

Tulu

Amgen Posts Higher 1Q Profit, Revenue

6. apr 2026, 17:09 UTC

Suurimad hinnamuutused turgudel

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3. veebr 2026, 21:49 UTC

Tulu

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6. jaan 2026, 15:14 UTC

Omandamised, ülevõtmised, äriostud

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19. nov 2025, 21:55 UTC

Suurimad hinnamuutused turgudel

Amgen Lung Cancer Drug Gets Full Approval From FDA

30. apr 2026, 20:01 UTC

Tulu

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30. apr 2026, 20:01 UTC

Tulu

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30. apr 2026, 20:01 UTC

Tulu

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30. apr 2026, 20:01 UTC

Tulu

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30. apr 2026, 20:01 UTC

Tulu

Amgen 1Q Adj EPS $5.15 >AMGN

30. apr 2026, 20:01 UTC

Tulu

Amgen 1Q Rev $8.62B >AMGN

30. apr 2026, 20:01 UTC

Tulu

Amgen 1Q Net $1.82B >AMGN

30. apr 2026, 20:01 UTC

Tulu

Amgen 1Q EPS $3.34 >AMGN

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4. veebr 2026, 19:56 UTC

Market Talk

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q Adj EPS $5.29 >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q Net $1.33B >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q Rev $9.9B >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen Sees FY Rev $37B-$38.4B >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3. veebr 2026, 21:01 UTC

Tulu

Amgen 4Q EPS $2.45 >AMGN

28. jaan 2026, 17:47 UTC

Tulu

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6. jaan 2026, 14:01 UTC

Omandamised, ülevõtmised, äriostud

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6. jaan 2026, 14:01 UTC

Omandamised, ülevõtmised, äriostud

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6. jaan 2026, 14:00 UTC

Omandamised, ülevõtmised, äriostud

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Võrdlus sarnastega

Hinnamuutus

Amgen Inc Prognoos

Hinnasiht

By TipRanks

8.47% tõus

12 kuu keskmine prognoos

Keskmine 364.7 USD 8.47%

Kõrge 427 USD

Madal 300 USD

Põhineb 24 Wall Streeti analüütiku instrumendi Amgen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

24 ratings

Osta

Hoia

Müü

Põhineb 24 analüütiku instrumendi Amgen Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

270.44 / 276.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

81 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.